Pharma BD Deal Intelligence
Novo Nordisk's AI-discovery bet on Valo's Opal platform nearly doubled in scope: the original $60M-upfront, up to 11-program cardiovascular collaboration expanded into obesity and type 2 diabetes, growing to up to 20 programs with up to $190M in near-term payments.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novo Nordisk is paying Valo Health $60 million upfront and up to $2.76 billion in milestones to collaborate on AI-discovered cardiometabolic drug targets,…
Novo Nordisk announced a discovery and development collaboration with Boston-based Valo Health, agreeing to pay up to $2.76 billion plus undisclosed upfront…
Novo Nordisk IR confirmation of the Jan 8, 2025 expanded Valo Health collaboration: up to 20 programs across obesity, type 2 diabetes and cardiovascular…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Novo Nordisk and Valo Health entered a discovery/development collaboration on Sept 25, 2023, leveraging Valo's Opal Computational Platform and proprietary human dataset to identify novel cardiovascular/cardiometabolic targets. Original terms: $60M in upfront/near-term payments and eligibility for up to $2.7B across up to 11 programs in milestones, plus R&D funding and royalties. On Jan 8, 2025 the partners EXPANDED the alliance: scope broadened to obesity and type 2 diabetes in addition to cardiovascular disease, the program count rose to up to 20 (9 new programs), and Valo became eligible for ~$4.6B in milestones with up to $190M in near-term payments (upfront plus an equity investment by Novo Nordisk and a potential near-term milestone), again with R&D funding and tiered royalties. Novo's CSO Marcus Schindler cited first-year progress and the addition of several novel cardiometabolic targets as the rationale for the expansion. Note: Valo's separate wholly-owned ROCK inhibitor OPL-0401 failed its Phase 2 diabetic-retinopathy endpoint and was suspended; that asset is outside the Novo collaboration and does not bear on this deal's programs.
127M US cases/yr · $97.0B Global cardiovascular therapeutics market (2023)
Cardiovascular disease (CVD) remains the leading cause of death in the U.S., with approximately 700,000 deaths per year and 127 million adults (roughly half of all U.S. adults) living with some form of cardiovascular disease. The cardiometabolic umbrella extends to obesity (~100M U.S. adults), type 2 diabetes (~37M), NASH/MASH (~16M symptomatic, 5M advanced fibrosis), and atherosclerotic CVD including heart failure with preserved ejection fraction (HFpEF) and coronary artery disease. The therapeutic landscape has been transformed by GLP-1 receptor agonists — Novo Nordisk's semaglutide (Wegovy/Ozempic/Rybelsus) and Lilly's tirzepatide (Zepbound/Mounjaro) — with 2023 U.S. sales approaching $25B combined and runway clearly extending into obesity-adjacent indications (cardiovascular outcomes, HFpEF, sleep apnea, MASH, kidney disease). Novo's partnership with Valo Health targets novel cardiometabolic drug targets discovered via Valo's Opal Computational Platform — leveraging de-identified longitudinal patient data from the Flatiron Health acquisition and Valo's in-house wet-lab validation — to identify small-molecule or oral peptide targets outside the GLP-1 class for cardioprotective or complementary MOAs.
The cardiometabolic competitive landscape is a two-tier structure. The GLP-1/dual-agonist class dominates commercial growth: Ozempic, Wegovy, Rybelsus (semaglutide, Novo Nordisk), Mounjaro, Zepbound (tirzepatide, Eli Lilly), with next-gen entrants including retatrutide (GGG triagonist, Lilly), orforglipron (oral GLP-1, Lilly), survodutide (GLP-1/glucagon, Boehringer/Zealand), and CagriSema (cagrilintide-semaglutide, Novo). PCSK9 inhibitors (Repatha/Amgen, Praluent/Regeneron-Sanofi, Leqvio/Novartis) target LDL. SGLT2 inhibitors (Jardiance, Farxiga) dominate CV/renal outcome trials. Emerging modalities include AZD8233/ION449 (APOC3 ASO, Ionis/AZ) for hypertriglyceridemia, olpasiran (Lp(a) siRNA, Amgen) Phase 3, pelacarsen (Lp(a) ASO, Novartis). The Novo/Valo collaboration targets novel non-GLP-1 MOAs identified through ML/AI discovery against human data, positioned to complement rather than cannibalize Novo's semaglutide/CagriSema franchise.
Novo Nordisk and Valo Health expanded their 2023 AI drug-discovery collaboration. Scope broadened to obesity and type 2 diabetes alongside cardiovascular disease; program count rose to up to 20 (9 new); Valo eligible for ~$4.6B in milestones with up to $190M near-term (upfront + Novo equity investment + potential milestone), plus R&D funding and royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Valo Health, Inc. (this deal) | 2023 | $4.8B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2023 deals · Novo Nordisk A/S deals · Cardiovascular deals